MONTREAL, MAY 7, 2019 – ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that it has entered into a manufacturing and collaboration agreement with Comprehensive Cell Solutions (CCS), a division of New York Blood Center (NYBC) for the clinical grade production of ExCellThera’s lead cell therapy product, ECT-001. [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
ElevateBio to Create a Portfolio of Innovative Cell and Gene Therapy Companies
– ElevateBio to leverage its fully integrated, company building bench-to-bedside capabilities exclusively focused on cell and gene therapies
– ElevateBio’s BaseCamp, an R&D, process development and cGMP manufacturing subsidiary, provides cell and gene expertise for all ElevateBio portfolio companies and selected strategic partners
– $150 MM Series A financing co-led by UBS Oncology Impact Fund Managed by MPM Capital and F2 Ventures joined by EcoR1 Capital, Redmile Group, and Samsara BioCapital
CAMBRIDGE, Mass. — ElevateBio, a Cambridge-based biotechnology holding company, today announced operations to create and build a broad portfolio of cell and gene therapy companies through partnerships with leading academic researchers, medical centers and entrepreneurs. [Read more…]
Famicord, Europe’s Largest Cord Blood Bank, and India’s CelluGen, Sign Letter of Intent
FamiCord Group, the largest cord blood bank in Europe, and CelluGen Biotech, a biotech company headquartered in Gurgaon, India, have signed a letter of intent (LOI) to cooperate across a range of business activities. Dated April 25, 2019, the specifics of the LOI state that the companies will pursue cooperation within the “field of family cord blood banking of stem cells and the use of stem cells in experimental and standard therapies.” The companies may jointly develop ATMPs and drugs. [Read more…]
ExCellThera’s Cell Expansion Technology, ECT-001, Receives FDA RMAT Designation
MONTREAL, April 23, 2019 — ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that the U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to its lead technology, ECT-001, in the treatment of hematologic malignancies. The RMAT designation is based on strong data from Phase I/II clinical trials using ECT-001 to expand stem and immune cells for the treatment of blood cancers. [Read more…]
Talaris Therapeutics Receives RMAT, Raises $100M, Announces Promising Phase II Data for Kidney Transplant
Talaris Therapeutics’ RMAT and Promising Phase 2 Data of Cell Therapy for Living Donor Kidney Transplant Recipients
BOSTON & LOUISVILLE, Ky.–Apr 18, 2019–Talaris Therapeutics, Inc., formerly Regenerex, a privately held biotechnology company developing transformative cell therapies that have the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients, today announced full results of its Phase 2 trial of FCR001 in living donor kidney transplant (LDKT) recipients. The therapy’s strong durability of benefit and safety profile support the initiation of a Phase 3 clinical trial in LDKT later this year.
- « Previous Page
- 1
- …
- 113
- 114
- 115
- 116
- 117
- …
- 145
- Next Page »